Press Release: Clearmind Medicine Commences Trading on the Frankfurt Stock Exchange

CANNANNEW REPORT

Toronto, Ontario–(Newsfile Corp. – August 18, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce the listing of its common shares for trading on the Frankfurt Stock Exchange (“FSE“) under the symbol CWY0. The FSE is the world’s third largest trading exchange, ranking only behind the New York Stock Exchange and NASDAQ. Home to public companies from more than 80 different countries, the FSE represents over 1.4 million securities and generates more than €1 trillion trading volume annually. “We are very pleased to have Clearmind shares dually-listed on the Frankfurt Stock Exchange. The increased visibility will help strengthen trading liquidity and facilitate investment in the Company by institutional and retail investors across Europe. The psychedelic drug market is expected to surpass $10 billion by 2027, and we believe Clearmind shares provide an excellent opportunity to participate in that growth,” commented Adi Zuloff-Shani, Ph.D., CEO of Clearmind.

Excerpt only …
READ MORE BELOW
Source : Press Release: Clearmind Medicine Commences Trading on the Frankfurt Stock Exchange

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.